Nebenwirkungen · Olumiant
Olumiant 1 mg film-coated tablets Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13–14
HOS-134814 · Präparat HOS-097616
Lipid elevations In the integrated data from rheumatoid arthritis, atopic dermatitis and alopecia areata clinical trials, baricitinib treatment was associated with dose-dependent increases in lipid parameters including total cholesterol, LDL cholesterol, and high density lipoprotein (HDL) cholesterol. There was no change in the LDL/HDL ratio. Elevations were observed at 12 weeks and remained stable thereafter at a higher value than baseline including in the long-term extension study in rheumatoid arthritis. Mean total and LDL cholesterol increased through week 52 in patients with atopic dermatitis and alopecia areata. In 13 rheumatoid arthritis clinical trials, baricitinib treatment was associated with dose-dependent increases in triglycerides. There was no increase in triglycerides levels in atopic dermatitis and alopecia areata clinical trials.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T16:57:00Z · SHA-256 21fbeaddabb6b542aa078c68b96c452bd5c5e255d57f8087fb5e2094fcf4ef31 · Passage 3e3988b1927d2e7e29b1a9ddfd478a4711e2c52d10771327d0f144d6f2ea16ad · Zeichen 6418–7330 im Abschnitt